{"id":203069,"name":"GLOBAL BLOOD THERAPEUTICS","slug":"global-blood-therapeutics","state":"CA","country":"United States of America","description":"","totalSpending":3290378,"filings":20,"yearlySpending":[{"year":2018,"income":130500},{"year":2019,"income":574698},{"year":2020,"income":585180},{"year":2021,"income":780000},{"year":2022,"income":1220000}],"issues":[{"code":"PHA","display":"Pharmacy"},{"code":"TRD","display":"Trade (domestic/foreign)"},{"code":"TAX","display":"Taxation/Internal Revenue Code"},{"code":"HCR","display":"Health Issues"},{"code":"MMM","display":"Medicare/Medicaid"}],"firms":["GLOBAL BLOOD THERAPEUTICS"],"lobbyists":["HEIDI WAGNER","AARON KRUPP","MOLLY RYAN"],"govEntities":["Health & Human Services, Dept of (HHS)","HOUSE OF REPRESENTATIVES","SENATE","White House Office","Centers For Medicare and Medicaid Services (CMS)"],"sampleDescriptions":["Medicare and Medicaid Policy\nDrug Pricing\nACA-related Issues\nIssues relating to FDA Approval\nIntellectual Property\nTax issues, including tax reform, OD tax credit\nTrade issues","Medicare and Medicaid Policy\nDrug Pricing\nACA-related Issues\nIssues relating to FDA Approval\nIntellectual Property\nTax issues, including tax reform, OD tax credit\nTrade issues","Medicare and Medicaid Policy\nDrug Pricing\nACA-related Issues\nIssues relating to FDA Approval\nIntellectual Property\nTax issues, including tax reform, OD tax credit\nTrade issues","Medicare and Medicaid Policy\nDrug Pricing\nACA-related Issues\nIssues relating to FDA Approval\nIntellectual Property\nTax issues, including tax reform, OD tax credit\nTrade issues","Medicare and Medicaid Policy\nDrug Pricing\nACA-related Issues\nIssues relating to FDA Approval\nIntellectual Property\nTax issues, including tax reform, OD tax credit\nTrade issues"]}